Table 3. Chromosomal Anomalies by Nuchal Translucency Measurement^a.

Nuchal translucency measurement, mm	Main analysis				Subgroup analysis, adjusted modelb
	Crude model		Adjusted modelb		Conditions identifiable on cfDNA screeningc		Conditions not identifiable on cfDNA screeningd
	RD (95% CI), %	RR (95% CI)	RD (95% CI), %	RR (95% CI)	RD (95% CI), %	RR (95% CI)	RD (95% CI), %	RR (95% CI)
<2.0	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
2.0 to <2.5	0.55 (0.45-0.66)	1.97 (1.78-2.18)	0.61 (0.51-0.71)	2.39 (2.14-2.66)	0.45 (0.37-0.52)	4.21 (3.62-4.91)	0.16 (0.08-0.23)	1.48 (1.27-1.73)
2.5 to <3.0	2.24 (1.85-2.63)	4.92 (4.26-5.69)	2.26 (1.88-2.63)	5.93 (5.11-6.88)	2.01 (1.67-2.34)	14.76 (12.33-17.65)	0.27 (0.08-0.46)	1.82 (1.34-2.47)
3.0 to <3.5	9.95 (8.49-11.41)	18.42 (15.92-21.31)	9.94 (8.49-11.39)	20.33 (17.58-23.52)	8.62 (7.27-9.96)	52.15 (43.98-61.84)	1.40 (0.77-2.04)	4.97 (3.45-7.17)
3.5 to <5.0	24.36 (21.71-27.00)	43.63 (38.88-48.96)	24.31 (21.67-26.96)	42.94 (38.28-48.16)	21.10 (18.60-23.61)	107.31 (93.20-123.56)	3.50 (2.27-4.72)	10.15 (7.37-13.98)
5.0 to <6.5	48.72 (43.51-53.94)	86.28 (76.91-96.80)	48.68 (43.46-53.89)	80.85 (71.91-90.90)	43.97 (38.79-49.15)	208.01 (179.77-240.69)	5.15 (2.66-7.64)	14.17 (9.02-22.25)
≥6.5	59.66 (54.99-64.33)	105.44 (96.40-115.32)	59.64 (54.97-64.31)	101.88 (92.79-111.88)	55.79 (51.06-60.53)	276.14 (244.84-311.44)	4.30 (2.18-6.41)	12.11 (7.69-19.07)

Abbreviations: cfDNA, cell-free DNA; RD, risk difference; RR, risk ratio.

^a Outcome determined by cytogenetic testing. Not having the outcome is determined by normal cytogenetic testing result if performed, normal cfDNA screen result if condition was tested, and by live birth without clinical findings if condition can be clinically diagnosed.

^b Adjusted for gestational age at screening.

^c Includes trisomies 21, 18, and 13 and sex chromosome aneuploidies.

^d Includes all other chromosomal anomalies.